Good news for those interested in AmbAgon's screening technologies: as of this week, their new website is live!
This American-Dutch medtech company, based at Twice hub Catalyst in Eindhoven and in San Francisco, discovered a new approach to drug development for metastatic breast cancer with its innovative research on stabilization of protein-protein interactions. A groundbreaking method that is changing the future of cancer patients and their compliance.
AmbAgon has developed small-molecule screening technologies aimed at discovering molecules that stabilize the direct interaction of oncogenic transcription factors with so-called 14-3-3 proteins, thereby inhibiting their pathological activities. This approach, to enhance the endogenous tumor-suppressive functions of 14-3-3 within different types of breast cancer with small molecule drugs, provides a radically new entry. A method long sought by the pharmaceutical industry and much needed in the clinic.
Ambagon's platform approach also opens up opportunities to address other important unmet clinical needs.
